NRx Pharmaceuticals, Inc. Q4 FY2025 earnings call

2025 was pivotal for NRX. Advancement of development programs: ANDA for Ketafree with FDA progress like bioequivalence determination, citizen petition on preservative, patent filing. NRX100 with FDA policy change enabling NDA filing using real-world evidence, expanded fast-track designation, potential for National Priority Voucher Program. NRX101 program transformed with D-cycloserine's potential with TMS, appointment of CMO, patentable sustained release, expanded access program, planned phase three trial, market estimate over $1 billion. Hope Therapeutics clinics EBITDA positive, revenue growth, acquisitions, opening new clinics, partnership with NeuroCare AG

For the year ended December 31st, 2025, NRX Pharmaceuticals reduced its loss from operations by approximately $2.3 million to $16.2 million from $18.5 million for the year ended December 31st, 2024. Research and development expense decreased by approximately $2.4 million to $3.8 million compared to $6.2 million in 2024. General and administrative expense decreased by approximately $0.4 million to $13.1 million compared to $13.5 million in 2024. As of December 31st, 2025, cash and cash equivalents were approximately $7.8 million

Management anticipates adequate cash resources to support operations at least through 2026, aiming to be fully commercial pharmaceutical company by then with larger clinical network

Certain statements are forward-looking subject to risks and uncertainties in federal securities laws, actual results may differ from expectations. Factors in periodic reports could cause results to differ from forward-looking statements

Q: Update on Ketofree inventory and market confidence.

A: Manufactured three registration batches, warehouse inventory, market potential.

Q: DCS extended release.

A: In vitro work, steady state importance, Dr. Brown's expertise.

Q: NRX100 Type C meeting and real-world data.

A: FDA allows NDA filing with existing trials and real-world data, broader indication impact on payer and prescriber.

Q: ANDA final approval remaining steps.

A: Office of Generic Drugs processes, stability data review, plant inspection.

Q: Ketafree commercial strategy.

A: Hospitals via existing distributors, clinics via medical liaison service